title: IVIG in autoimmune disease - Potential next generation biologics.
abstract: Polyclonal plasma-derived IgG is a mainstay therapeutic of immunodeficiency disorders as well as of various inflammatory autoimmune diseases. In immunodeficiency the primary function of IVIG/SCIG is to replace missing antibody specificities, consequently a diverse Fab-based repertoire is critical for efficacy. Attempts to capture the Ig repertoire and express it as a recombinant IVIG product are currently ongoing. Likewise correction of the defective genes by gene therapy has also been tried. However, both approaches are far from becoming mainstream treatments. In contrast, some of the most important effector mechanisms relevant in therapy of autoimmunity are based on the Fc-portion of IgG; they include scavenging of complement and blockade/modulation of IgG receptors (Fc gamma receptor [FcγR] or the neonatal Fc receptor [FcRn]). These effects might be achieved with appropriately formulated Fc-fragments instead of full-length IgG, as suggested by a pilot study with monomeric plasma-derived Fc in children with ITP and in Kawasaki disease in the 1990s. Since then it has been proposed that structured multimerization of Fc fragments might confer efficacy at much lower doses than with IVIG. Accordingly, various molecular strategies are currently being explored to achieve controlled Fc multimerization, e.g. by fusion of IgG1 Fc to the IgG2 hinge-region or to the IgM tail-piece. Safety considerations will be crucial in the evaluation of these new entities. In a different approach, mutant Fc fragments and monoclonal antibodies have been designed for blockade of the FcRn.
authors.affiliation: CSL Behring AG, Research, Switzerland. Electronic address: adrian.zuercher@cslbehring.com.
authors.forename: Adrian W
authors.initials: AW
authors.lastname: Zuercher
authors.affiliation: CSL Behring AG, Research, Switzerland.
authors.forename: Rolf
authors.initials: R
authors.lastname: Spirig
authors.affiliation: CSL Ltd, Research, Australia.
authors.forename: Adriana
authors.initials: A
authors.lastname: Baz Morelli
authors.affiliation: CSL Behring AG, Research, Switzerland.
authors.forename: Fabian
authors.initials: F
authors.lastname: Käsermann
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000627:therapeutic use; D007136:Immunoglobulins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D007249:Inflammation / Q000188:drug therapy; D007279:Injections, Subcutaneous; D011961:Receptors, Fc / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products; D007141:Immunoglobulin Fc Fragments; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D011961:Receptors, Fc
keywords: Auto-antibodies; Auto-immune disease; IVIG; Multimerized Fc; Recombinant